Kristina Hellman

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

D. Katsaros, F. Marmé, M. Yunokawa, 2023, The Lancet.

Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.

P. Kjølhede, P. Dahm-Kähler, C. Borgfeldt, 2024, Gynecologic oncology.